Structural basis of valmerins as dual inhibitors of GSK3β/CDK5

被引:30
|
作者
Li, Xiaolong [1 ]
Wang, Xiaowei [2 ]
Tian, Zibin [2 ]
Zhao, Houling [1 ]
Liang, Da [1 ]
Li, Weisong [1 ]
Qiu, Yujin [1 ]
Lu, Shaoyong [3 ]
机构
[1] Weifang Med Univ, Affiliated Hosp, Depatment Spinal Surg, Weifang 261000, Peoples R China
[2] Qingdao Univ, Coll Med, Affiliated Hosp, Dept Gastroenterol, Qingdao 266003, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med, Med Bioinformat Ctr, Shanghai 200025, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
GSK3; beta/CDK5; MD simulation; Molecular docking; MM-PBSA; PCA; MOLECULAR-DYNAMICS SIMULATION; CANCER-THERAPY; KINASE; MECHANISM; BINDING; RESISTANCE; MUTATION; MUTANTS;
D O I
10.1007/s00894-014-2407-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Development of multi-target drugs is becoming increasingly attractive in the repertoire of protein kinase inhibitors discovery. In this study, we carried out molecular docking, molecular dynamics simulations, molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) binding free energy calculations, principal component analysis (PCA), and dynamical cross-correlation matrices (DCCM) to dissect the molecular mechanism for the valmerin-19 acting as a dual inhibitor for glycogen synthase kinase 3 beta (GSK3 beta) and cyclin-dependent kinase 5 (CDK5). Detailed MM-PBSA calculations revealed that the binding free energies of the valmerin-19 to GSK3 beta/CDK5 were calculated to be -12.60 +/- 2.28 kcal mol(-1) and -11.85 +/- 2.54 kcal mol(-1), respectively, indicating that valmerin-19 has the potential to act as a dual inhibitor of GSK3 beta/CDK5. The analyses of PCA and DCCM results unraveled that binding of the valmerin-19 reduced the conformational dynamics of GSK3 beta/CDK5 and the valmerin-19 bound to GSK3 beta/CDK5 might occur mostly through a conformational selection mechanism. This study may be helpful for the future design of novel and potent dual GSK3 beta/CDK5 inhibitors.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 50 条
  • [21] GSK3 Inhibitors and Disease
    Hernandez, Felix
    Diaz Nido, Javier
    Avila, Jesus
    Villanueva, Nieves
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2009, 9 (09) : 1024 - 1029
  • [22] Dopamine D1 receptor activation induces tau phosphorylation via cdk5 and GSK3 signaling pathways
    Lebel, Manon
    Patenaude, Christian
    Allyson, Julie
    Massicotte, Guy
    Cyr, Michel
    NEUROPHARMACOLOGY, 2009, 57 (04) : 392 - 402
  • [23] Aminothiazole analogs as CDK5 inhibitors
    Jain, Prashi
    Shah, Dhruv
    Flaherty, Patrick
    Madura, Jeffry
    Meijer, Laurent
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [24] Rational design of potent GSK3β inhibitors with selectivity for Cdk1 and Cdk2
    Lesuisse, Dominique
    Dutruc-Rosset, Gilles
    Tiraboschi, Gilles
    Dreyer, Matthias K.
    Maignan, Sebastien
    Chevalier, Alain
    Halley, Frank
    Bertrand, Philippe
    Burgevin, Marie-Claude
    Quarteronet, Dominique
    Rooney, Thomas
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (06) : 1985 - 1989
  • [25] Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3β
    Liu, F
    Iqbal, K
    Grundke-Iqbal, I
    Gong, CX
    FEBS LETTERS, 2002, 530 (1-3) : 209 - 214
  • [26] Structural Plasticity of Dendritic Spines Requires GSK3α and GSK3β
    Cymerman, Iwona A.
    Gozdz, Agata
    Urbanska, Malgorzata
    Milek, Jacek
    Dziembowska, Magdalena
    Jaworski, Jacek
    PLOS ONE, 2015, 10 (07):
  • [27] New approaches to the discovery of cdk5 inhibitors
    Glicksman, Marcie A.
    Cuny, Gregory D.
    Liu, Min
    Dobson, Brittany
    Auerbach, Kenneth
    Stein, Ross L.
    Kosik, Kenneth S.
    CURRENT ALZHEIMER RESEARCH, 2007, 4 (05) : 547 - 549
  • [28] GSK3 as a pathogenic kinase in tauopathy and the use of GSK3 inhibitors such as Lithium as a therapeutic
    Duff, Karen
    Planel, Emmanuel
    Noble, Wendy
    MOVEMENT DISORDERS, 2008, 23 (08) : 1197 - 1197
  • [29] Novel aspects in structure-activity relationships of profiled 1-aza-9-oxafluorenes as inhibitors of Alzheimer's disease-relevant kinases cdk1, cdk5 and gsk3β
    Tell, Volkmar
    Mahmoud, Kazem Ahmed
    Wichapong, Kanin
    Schaechtele, Christoph
    Totzke, Frank
    Sippl, Wolfgang
    Hilgeroth, Andreas
    MEDCHEMCOMM, 2012, 3 (11) : 1413 - 1418
  • [30] Novel dual-targeting PROTAC degraders of GSK-3(3 and CDK5: A promising approach for pancreatic cancer treatment
    Neerasa, Jayaprakash
    Kim, Bongsu
    Chung, Hunsuk
    BIOORGANIC & MEDICINAL CHEMISTRY, 2025, 120